1 Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy. emanuel.raschi@unibo.it.
2 Université Bordeaux, INSERM, Bordeaux Population Health, U1219, AHeaD Team, Bordeaux, France.
3 CHU de Bordeaux, Pôle de Santé Publique, Service de Pharmacologie Médicale, Bordeaux, France.
4 Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel St, London, WC1E 7HT, UK.
5 GlaxoSmithKline, Brentford, UK.
6 Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy.
7 Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
8 Unit of Adverse Drug Reaction Monitoring, University Hospital of Pisa, Pisa, Italy.
9 Netherlands Pharmacovigilance Centre Lareb, 5237 MH, 's-Hertogenbosch, The Netherlands.
10 Groningen Research Institute of Pharmacy, PharmacoTherapy-Epidemiology and Economics, University of Groningen, 9713 AV, Groningen, The Netherlands.
11 Adis Journals, Springer Nature, Auckland, New Zealand.
12 Pharmacovigilance Department, Grenoble Alpes University Hospital, 38043, Grenoble, France.
13 University Grenoble AlpesInserm U1300, HP2, 38000, Grenoble, France.
14 University Grenoble AlpesInserm CIC1406, Grenoble Alpes University Hospital, 38000, Grenoble, France.
15 Centre Regional de Pharmacovigilance, CHU Grenoble Alpes, CS 10217, 38043, Grenoble Cedex 9, France.